Since there are not enough evidences suggesting that BIM deletion polymorphism is related to TKI-resistance in CML patients, we propose the common BIM deletion should not serve as a biomarker for determining the prognosis in CML patients with the treatment of TKIs. Here, BCL2L11 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.